CT-868-004
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus
Sponsor
Study Purpose: To evaluate the safety and tolerability of the study drug, CT-868, and to study the effect that CT-868 has on Type 1 Diabetes and weight.
To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:
Study Duration: 25 Weeks
Age: 18+ years old
Sex: Male & Female
Conditions/Eligibility: Male or Female, 18+ years of age.
Diagnosed with Type 1 Diabetes for at least 1 year.
BMI of 27 or higher.
Currently receiving insulin treatment.
Must be wearing a CGM.
Must be a non-smoker.
Study Procedures: 1 Screening visit: informed consent, vitals, blood draw, medication and medical history review, physical exam, pregnancy test, urinalysis and urine drug screen, 12-lead ECG
12 outpatient visits at the study site
8 phone calls
Compensation: Up to $2150.00
This study is currently enrolling.